Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal... BACKGROUND We quantified changes in prostate carcinoma vascularity treated with anti‐androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist®. METHODS Thirty‐six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist® (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre‐enhancement scores, arrival time, time to peak, peak value, and area under the time‐enhancement curve (AUC). These were compared to pre‐treatment values and serial PSA measurements. RESULTS The pre‐enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68% ± 9% (mean ± standard error) by week 1, 56% ± 9% by week 3, and 20% ± 4% by week 6. A strong correlation with changes in the mean PSA (r = 0.95, P < 0.001) was also measured. In four patients, Doppler indices did not fall with PSA: two patients with the most marked discrepancy relapsed at 6 months. CONCLUSION The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment. Prostate 51: 256–267, 2002. © 2002 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

Download PDF
12 pages

Loading next page...
 
/lp/wiley/quantitative-microbubble-enhanced-transrectal-ultrasound-as-a-tool-for-l8L2uG66i0

References (40)

Publisher
Wiley
Copyright
Copyright © 2002 Wiley Subscription Services
ISSN
0270-4137
eISSN
1097-0045
DOI
10.1002/pros.10065
pmid
11987154
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND We quantified changes in prostate carcinoma vascularity treated with anti‐androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist®. METHODS Thirty‐six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist® (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre‐enhancement scores, arrival time, time to peak, peak value, and area under the time‐enhancement curve (AUC). These were compared to pre‐treatment values and serial PSA measurements. RESULTS The pre‐enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68% ± 9% (mean ± standard error) by week 1, 56% ± 9% by week 3, and 20% ± 4% by week 6. A strong correlation with changes in the mean PSA (r = 0.95, P < 0.001) was also measured. In four patients, Doppler indices did not fall with PSA: two patients with the most marked discrepancy relapsed at 6 months. CONCLUSION The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment. Prostate 51: 256–267, 2002. © 2002 Wiley‐Liss, Inc.

Journal

The Prostate – Wiley

Published: Jan 1, 2002

Keywords: ; ; ;

There are no references for this article.